CA125 nadir values as a prognostic factor in epithelial ovarian cancer [7]

Journal of Clinical Oncology

Volumn 23, Issue 10, 2005, Pages 2435-2436

  Altundag, Kadri ^a   Altundag, Ozden ^a   Morandi, Paolo ^b   Gunduz, Mehmet ^c  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Department of Medical Oncology   (Italy)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; PACLITAXEL; TOPOTECAN; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LETTER; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; TREATMENT RESPONSE; DISEASE FREE SURVIVAL; FEMALE; NOTE; OVARY TUMOR; PATHOLOGY; PREDICTION AND FORECASTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CARBOPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TOPOTECAN;

EID: 17144378947     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.136     Document Type: Letter

References (2)

1. De Placido S, Scambia G, Di Vagno G, et al: Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 22:2635-2642, 2004
2. Crawford SM, Paul J, Reed NS, et al: The prognostic significance of the CA 125 nadir in patients that achieve CA 125 response. Proc Am Soc Clin Oncol 22:448, 2004 (abstr 5001)